Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model

PR Newswire February 2, 2021

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

PR Newswire February 1, 2021

Moleculin Announces Reverse Stock Split

PR Newswire January 29, 2021

Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference

PR Newswire January 7, 2021

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

PR Newswire December 29, 2020

Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

PR Newswire December 17, 2020

Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference

PR Newswire December 3, 2020

Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066

PR Newswire December 1, 2020

Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML

PR Newswire November 19, 2020

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020

PR Newswire November 13, 2020

Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19

PR Newswire October 29, 2020

Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare Event

PR Newswire October 27, 2020

Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors

PR Newswire October 21, 2020

Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial

PR Newswire October 13, 2020

Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV

PR Newswire October 6, 2020

Moleculin Appoints Elizabeth Cermak to Board of Directors

PR Newswire October 5, 2020

Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University

PR Newswire October 1, 2020

Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites

PR Newswire September 29, 2020

Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122

PR Newswire September 14, 2020

Moleculin to Present at Upcoming Healthcare Investor Conferences

PR Newswire September 10, 2020